poisar

Stocks · News reference

CNBC Halftime Report Final Trades: Thermo Fisher Scientific, State Street SPDR S&P Aerospace & Defense ETF, Pfizer

Benzinga Newsdesk
More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

PFETMOXAR
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  2. Leo Sun

    Here's How Many Shares of AbbVie You'd Need for $5,000 in Yearly Dividends

    AbbVie, a Dividend King with 53 consecutive years of dividend increases, would require 723 shares (approximately $206,358) to generate $5,000 in annual dividends at its current price. Despite a modest 2.4% forward yield, the pharmaceutical giant's strong portfolio of blockbuster drugs, low P/E ratio of 16, and 93% stock rally over three years make it an attractive long-term income investment, even compared to higher-yielding alternatives like Pfizer.

    ABBVPFE
  3. Matthew Benjamin

    Pfizer Just Declared Its 352nd Straight Quarterly Dividend. Is the 6% Yield Safe?

    Pfizer declared its 352nd consecutive quarterly dividend with a 5.9% yield, significantly higher than the S&P 500 average of 1%. While the company faces patent cliffs on major drugs like Eliquis and Xeljanz this year, it maintains a robust pipeline focused on cancer treatments and generated $11 billion in free cash flow over the past four quarters, exceeding dividend payments. Management remains committed to maintaining and growing the dividend, though investors must have confidence in the company's ability to replace expiring patents with new pipeline drugs.

    PFE
  4. The Motley Fool Team

    Johnson & Johnson: 3 Key Takeaways for Long-Term Investors

    Johnson & Johnson raised its full-year sales outlook after Q3 2026 operational revenue grew 6%, putting the company on track to exceed $100 billion in annual revenue for the first time. Strong pharmaceutical demand, particularly in cancer treatments, drove performance. However, the medical device segment faced headwinds with only 2.5% growth due to Middle East disruptions and China's bulk-buying program. Management plans to restore momentum through new product launches and is leaning toward spinning off its DePuy Synthes orthopedics subsidiary by mid-2027.

    JNJPFE